Lantern Pharma Inc. is an artificial intelligence‑focused biotechnology company dedicated to discovering and developing cancer therapies by transforming oncology drug discovery and development. The company’s core activity revolves around its proprietary RADR® platform, which integrates over 200 billion oncology‑focused data points drawn from multi‑omic datasets, drug‑tumor interactions, clinical records, scientific literature and mechanistic pathway data, and applies more than 200 machine‑learning algorithms to identify biomarker‑driven small‑molecule candidates and to rescue previously abandoned compounds. Lantern Pharma advances a pipeline that includes three clinical‑stage small‑molecule drug candidates—LP‑300, LP‑184, and LP‑284—and an antibody‑drug conjugate (ADC) program, while also developing a wholly‑owned subsidiary, Starlight Therapeutics, to focus on central nervous system indications for LP‑184 (branded STAR‑001).
Lantern Pharma Inc. generates revenue primarily through research collaborations, licensing agreements, and grant funding with pharmaceutical and academic partners. Notable collaborations include a May 2021 agreement with Actuate Therapeutics to utilize the RADR® platform for biomarker discovery, a February 2023 collaboration with TTC Oncology to accelerate development of the drug candidate TTC‑352, and a mid‑2024 partnership with Oregon Therapeutics to optimize the PDI inhibitor XCE853 using AI‑driven biomarker identification. The company also receives licensing revenue and milestone payments from arrangements such as the reacquisition of LP‑100 from Allarity Therapeutics and in‑licensed patents from AF Chemicals and BioNumerik Pharmaceuticals. Looking ahead, Lantern Pharma intends to monetize its AI platforms—RADR® and withZeta. AI—through subscription, access, and service models offered to biopharma companies, researchers, and drug developers. At present, the company has no approved commercial products and therefore does not derive revenue from product sales.
Lantern Pharma Inc. occupies a distinctive niche at the intersection of biotechnology and artificial intelligence‑driven drug development, differentiating itself through an AI‑enabled strategy that both rescues historical drug candidates and designs de‑novo compounds guided by biomarker signatures. The company competes with AI‑focused drug developers such as AbCellera, Atomwise, InSilico Medicine, Iktos, Verge Genomics, Recursion Pharmaceuticals, Schrodinger, and Roivant Sciences, as well as with oncology‑focused clinical‑stage companies including Candel Therapeutics, Pyxis Oncology, Foghorn Therapeutics, Prelude Therapeutics, Warewolf Therapeutics, Xilio Therapeutics, Ikena Oncology, Atossa Therapeutics, Elevation Oncology, and Bolt Biotherapeutics. Its competitive advantages stem from the scale and depth of the RADR® platform—over 200 billion data points and a library of 200+ ML algorithms—which enables rapid identification of biologically relevant genomic signatures and prediction of drug response, reducing the typical timeline from AI insight to first‑in‑human trials to two to three years and the associated cost to approximately $1.0‑$2.5 million per program. Additionally, Lantern Pharma’s pipeline benefits from multiple orphan drug, rare pediatric disease, and Fast Track designations from the FDA for indications such as glioblastoma, triple‑negative breast cancer, mantle cell lymphoma, and high‑grade B‑cell lymphoma, providing regulatory incentives and market exclusivity that further de‑risk development.
Lantern Pharma Inc. collaborates with a diverse set of biopharma partners, academic institutions, and research organizations to advance its drug candidates and AI platforms. Specific collaborators named in the filing include Actuate Therapeutics, TTC Oncology, Oregon Therapeutics, the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Georgetown University, the Danish Cancer Society‑Research Center, and the Greehey Children’s Cancer Research Institute. The company’s therapeutic focus spans multiple oncology indications, targeting patient populations in non‑small cell lung cancer (particularly never‑smoker adenocarcinoma), triple‑negative breast cancer, glioblastoma and other central nervous system cancers, pancreatic cancer, hematologic malignancies such as mantle cell lymphoma and diffuse large B‑cell lymphoma, and rare pediatric tumors like atypical teratoid rhabdoid tumors. Ultimately, the company’s therapies are intended to serve cancer patients who stand to benefit from biomarker‑driven, precision‑medicine approaches that match the right drug to the right patient.